EARLY DIAGNOSIS OF NOSOCOMIAL CANDIDIASIS

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 本研究的主要目的是： 1)普罗维登评估三种新的诊断新生儿侵袭性念珠菌病的试验。 2)建立临床表现的风险分层模型。 3)根据临床医生的判断来检验临床模型的可行性。 次要目标： 1)确定根据药物临床试验质量管理规范（GCP）评价终末器官损伤的新生儿中终末器官损伤的累积发生率。 2)确定从入选患者血液中分离的念珠菌的耐药模式和基因表达。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The Primary Aims of this study are: 1) Prospectively evaluate three new diagnostic tests for invasive neonatal candidiasis. 2) Develop a risk-stratification model on clinical presentation. 3) Test the peformance of the clinical model against the judgment of bedside clinicians. Secondary Aims: 1) Determine cumulative incidence for end-organ damage in those neonates who are evaluated for end-organ damage in accordance with Good Clinical Practice (GCP). 2) Determine resistance patterns and gene expression by Candida isolated from the blood of enrolled patients.